Seek­ing first-in-class glo­ry, Roche en­lists biotech part­ner that prides it­self on crack­ing 'un­drug­gable' tar­gets

Roche is on the hunt for some first-in-class projects — and, with the help of a new part­ner, it’s start­ing from scratch.

The phar­ma gi­ant has tapped Phore­Most, a small biotech work­ing out of Cam­bridge, UK, for a tar­get dis­cov­ery pact in which Phore­Most will de­ploy its screen­ing plat­form to­ward cer­tain dis­ease-rel­e­vant path­ways in hema­tol­ogy and im­munol­o­gy se­lect­ed by Roche.

Once Phore­Most iden­ti­fies those tar­gets, Roche will take over to fur­ther val­i­date and char­ac­ter­ize them.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER